Topical magnesium,
does it really help with Faster recovery of postexercise soreness, strength, and performance?
research showsThe grade is D. In a double-blind randomized trial of 35 healthy active adults, a commercial magnesium gel did not improve postexercise muscle soreness, peak isometric knee-extensor strength, creatine kinase, or interleukin-6 versus placebo gel. Primary soreness was 43 (SD 27) versus 41 (SD 26) at 24 hours and 42 (SD 31) versus 32 (SD 23) at 48 hours. Group means, standard deviations, and sample sizes allow simple confidence intervals to be reconstructed, but the formal repeated-measures-model interval cannot be reconstructed. No independent repeated null trial exists, so the grade is D with 28 points, not F.
ads claimWhether magnesium crosses skin and whether recovery becomes faster are different questions. Absorption studies and oral-magnesium exercise trials cannot be counted as recovery evidence for a topical gel.
Useful facts when choosing a product
- The tested commercial gel contained 0.53 mg/mL magnesium; retail sprays and oils may use different concentrations and vehicles.
- Verdict 1270 concerns the same topical route but uses spray or oil, whereas this verdict tested a gel; the formulations differ.
- Verdict 013 is D for generic magnesium and sleep or eyelid twitching, while verdict 1089 is C with 44 points for magnesium L-threonate and sleep; their interventions or endpoints differ.
What the research actually shows
Coates randomized 35 healthy active adults, 16 to magnesium gel and 19 to placebo gel, in a double-blind parallel design. Participants completed 40 minutes of downhill treadmill running, with gel applied to both thighs ten minutes before and immediately after exercise. Soreness mean plus or minus SD was 4 plus or minus 5 versus 4 plus or minus 5 at baseline, 28 plus or minus 20 versus 21 plus or minus 14 immediately after, 43 plus or minus 27 versus 41 plus or minus 26 at 24 hours, and 42 plus or minus 31 versus 32 plus or minus 23 at 48 hours. Approximate simple 95% confidence intervals for between-group differences were -5.3 to 19.3 immediately after, -16.4 to 20.4 at 24 hours, and -9.2 to 29.2 at 48 hours. These are unadjusted approximations, not the formal repeated-measures-model interval, which cannot be reconstructed.
Why this is classified as D (28)
A direct double-blind randomized trial was null for soreness, strength, and performance-related measures. With no independent repeated null trial and no confirmed confidence interval plus validated benefit threshold, the result is D with 28 points rather than F.
Counterpoint. The tested dose and two brief applications may not represent every higher-concentration product. Any different product still requires direct efficacy testing; absorption plausibility alone is insufficient.
Rejudgment record. Cross-check applied — Cross-check of the 2025 original report for design, absolute soreness, strength, and damage-marker values, public confidence-interval availability, plus a repeated search for independent topical trials in the same indication
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced postexercise muscle soreness | D | The primary soreness VAS did not differ from placebo. |
| Recovery of strength and performance | D | Peak isometric strength and functional recovery showed no treatment effect. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Randomized double-blind placebo-gel controlled parallel trial | 48 | Manufacturer funding could not be confirmed from publicly accessible material | Primary sit-to-stand soreness VAS; strength, creatine kinase, and interleukin-6 | Means, standard deviations, and sample sizes permit simple confidence intervals, but not the formal repeated-measures-model interval. | Only direct topical exercise-recovery randomized trial |
Receipt — 1 References
Of 1 cited sources, 1 had limited original-page access (blocked or summary-only) and were verified via index/summary, marked partial; the rest were verified at the original page. As of 2026-08-06.
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-06 · Corrections: none
Cite this verdict
[Chamgap] Topical magnesium x faster exercise recovery — Evidence Grade D·28. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/topical-magnesium-exercise-recovery/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.